Share this video  

ESMO 2018 | Advancing lung cancer therapy: from palliative chemotherapy to immunotherapy

James Spicer, FCRP, PhD, MRCP, MBBS, of the Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the value of PD-L1 in lung cancer treatment, after highlighting the rapid progress that has been made in therapeutics for lung cancer, where previously, palliative chemotherapy was the only stand-alone treatment option. Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Professor Spicer, points out that PD-L1 is the most well known biomarker to help guide lung cancer immunotherapy.